Clinical appearance raises suspicion; histology and extent guide treatment. No single operation or topical protocol fits every tumour.
Terminology and draft status
Terminology review is not complete. No new WHO UMD entry verification is claimed for this copy; pending entries and limits are recorded in terminology.md.
01Describe the lesion and the patient context
Record duration, growth, recurrence, symptoms, previous skin cancer, UV exposure and immune suppression, including HIV where relevant. Population differences in incidence do not make ethnicity a stand-alone predictor of aggressiveness; the export’s claim of intrinsically more aggressive SCC in darker skin is not established. 1
Measure and photograph the lesion with its site, pigmentation, surface and vessels. Examine the entire conjunctiva, evert the lids and inspect the tarsal surfaces and fornices; a cotton applicator may help lower-lid exposure without traumatizing the mass. Look for deep extension using UBM and selected anterior-segment OCT; neither imaging replaces necessary histology. 1
Feeder vessels and fixation to sclera increase suspicion but do not prove metabolic activity or invasion. Examine preauricular, submandibular and cervical nodes as appropriate: lateral drainage often reaches preauricular/parotid nodes and medial drainage submandibular nodes, with overlap. Stage according to tumour type and findings, rather than ordering identical systemic tests for every lesion. 1
02Separate epithelial dysplasia from invasive SCC
Ocular surface squamous neoplasia (OSSN) includes conjunctival intraepithelial neoplasia (CIN), carcinoma in situ and invasive squamous cell carcinoma (SCC). CIN grades1–3 describe epithelial involvement by thirds; invasion through the basement membrane changes the diagnosis. Gelatinous, papilliform and leukoplakic appearances overlap and cannot stage invasion alone. 1
The export’s AJCC8 summary lists T1 up to5mm, T2 above5mm, T3 adjacent structures and T4 orbit. This needs the in-situ category and invasion/site qualifiers: size alone cannot assign all stages, and orbital extension is distinct. Use the exact current conjunctival SCC staging table when documenting a patient; the full staging source remains pending. 1
A planned no-touch excision avoids grasping the tumour and contamination of the field; it is not a ban on all diagnostic contact or on properly planned biopsy. The original2–4mm margin is a selected surgical range, not a rule independent of site, depth and reconstruction. Orient tissue and agree transport with pathology; consider margin treatment and adjuvant therapy according to histology and residual disease. 1
Topical MMC and interferon-alpha-2b are specialist options, particularly for selected diffuse/intraepithelial disease; deep invasive masses may need another approach. The original MMC0.04% for4weeks followed by2weeks off is not a universal prescription. Regimens differ, and epithelial toxicity, punctal stenosis and limbal stem-cell injury require monitoring. Punctal plugs can protect drainage in selected cases but are not compulsory or a guarantee against damage; possible tumour involvement of drainage structures changes the decision. 1 2
03Assess pigmentation, atypia and extent
A conjunctival naevus, primary acquired melanosis (PAM) and melanoma need different management. Histological atypia and extent matter; the original30% transformation figure is not the risk of every PAM. Map biopsies help selected extensive or multifocal lesions, rather than being obligatory for every pigmented spot. An amelanotic lesion can also be malignant. 1
Conjunctival melanoma may harbour BRAF or NRAS alterations; GNAQ/GNA11 are associated with uveal melanocytic tumours and some melanocytosis. These are associations, not sufficient diagnoses or interchangeable treatment targets. Nivolumab/ipilimumab may be considered in selected metastatic conjunctival disease, but this does not establish the same response in uveal melanoma; the oncology team needs the exact tumour and molecular context. 1
Excision with margin control and selected cryotherapy or plaque radiotherapy, including Ru-106, can improve local management. Neither adjuvant treatment is compulsory for every case. The original recurrence above50% and mortality above35% after15years need the population, stage and treatment era; they are not universal counselling estimates. Long-term local, nodal and systemic surveillance remains important. 1
04Recognise masquerade lesions and obtain suitable tissue
A pearly edge, telangiectasia, ulceration and loss of lashes suggest basal cell carcinoma (BCC). Its main danger is local destruction; metastasis is rare. The quoted90–95% share of malignant eyelid tumours varies by population. Histological margin control, by Mohs or another appropriate method, guides treatment; Mohs is not the only treatment for every eyelid malignancy. 1
An atypical recurrent chalazion or persistent unilateral treatment-resistant blepharoconjunctivitis should raise concern for sebaceous carcinoma. Plan an adequately deep, representative biopsy and tell pathology the suspected diagnosis; map conjunctiva when pagetoid spread is suspected. Not every recurrent chalazion is cancer. A rapidly growing reddish-violet Merkel-cell lesion also needs prompt diagnosis and staging; the quoted50%5-year survival is stage-dependent and not a personal prognosis. 1
05Restore protection after tumour control
Reconstruction restores lid closure, both lamellae and a stable ocular surface while preserving tumour surveillance. Direct closure may suit defects below1/3 of lid width, depending on laxity and location; larger defects can need a Hughes flap for the lower lid or another vascularized reconstruction. The export’s term Youse-Plastik is unresolved and is not silently substituted with another named operation. 1
Amniotic membrane can cover selected surface defects; oral mucosa supplies a lining and is not mechanically identical to tarsus. Limbal stem-cell loss needs a dedicated reconstruction plan: simple limbal epithelial transplantation (SLET) requires an appropriate donor and disease setting and is not the answer to every total loss. Extensive facial involvement needs coordinated oculoplastic, oncology and sometimes maxillofacial care, rather than an automatic single-specialty referral rule. 1
06Evaluate iris and ciliary-body extension deliberately
Many iris lesions are incidental and some iris melanomas have a better prognosis than posterior uveal disease, but ciliary-body involvement, size and extraocular spread alter risk. Use serial documentation and UBM where appropriate. Rapid growth with inflammation also raises metastasis, including breast or lung origin, but does not establish metastasis over melanoma on its own. 1
A tumour team chooses whether tissue is needed and selects aspiration, cutter biopsy or surgical excision according to the lesion and purpose. Vitrector aspiration is an option, not the only lawful technique; properly planned forceps/scissor surgery is not inherently malpractice. Minimise seeding risk through specialist planning rather than attempting an unplanned biopsy. 1 3 4
07Match the lesion, investigation and treatment boundary
Before treatment, confirm lesion identity and extent, regional nodes where relevant, tissue handling and a follow-up plan. Do not convert warning signs into proven invasion, apply one MMC cycle to all tumours or mistake a no-touch principle for prohibition of every biopsy. Lymphoma requires suitable biopsy and systemic staging; radiotherapy or systemic treatment depends on subtype and extent. 1
| Tumour | Typical appearance | Investigation | Treatment approach | Warning |
|---|---|---|---|---|
| Eyelid BCC | Pearly edge, lash loss | Biopsy and margins | Margin-controlled excision, e.g. Mohs | Local destruction |
| Conjunctival SCC | Gelatinous or leukoplakic | Histology, UBM for depth | Selected excision/adjuvant MMC0.04%; individual regimen | Scleral fixation raises suspicion |
| Melanoma | Pigmented or amelanotic stromal lesion | Planned biopsy; mapping when needed | Excision; selected plaque/cryotherapy | Recurrence and metastasis; >35%/15years not universal |
| Lymphoma | Salmon patch | Suitable biopsy and staging | Radiotherapy/systemic therapy by subtype | Systemic involvement |
| Sebaceous carcinoma | Atypical recurrent chalazion | Representative deep biopsy | Oncological excision with margin control | Treatment-resistant blepharitis/pagetoid spread |
What are the main learning points?
Clinical appearance raises suspicion; histology and extent guide treatment. No single operation or topical protocol fits every tumour.
When is assessment urgent?
Rapid growth, new visual loss, severe pain, orbital signs or suspected invasive malignancy need prompt specialist assessment.
References and access status
- 1Immutable original export; anterior segment tumour lecture; examiner attribution unchecked
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 2Princess Margaret Cancer Centre conjunctival malignancy practice policy, May2019
Selected extracted examination and surgery/chemotherapy pp.5 and15–17 actually inspected16November2026; historic centre policy, not current whole-guideline/RCT appraisal.
- 3Small-incision iris tumour biopsy using sampling forceps,PMID24964795
Selected actual indexed primary technique descriptions inspected16November2026; small series,not comparative proof of universal safety; full reports/figures unread.
- 4Aspiration-cutter-assisted multifocal iris biopsy,PMID27228972
Selected actual indexed primary technique descriptions inspected16November2026; small series,not comparative proof of universal safety; full reports/figures unread.
Original lecture link
For patients
A new growth on the eye or eyelid is not automatically cancer. Changes in size, colour or behaviour need an examination and sometimes a tissue sample.
Examination and selected tests guide individual treatment and follow-up; this educational text cannot replace your own assessment.
Rapid growth, new visual loss, severe pain, orbital signs or suspected invasive malignancy need prompt specialist assessment.
Rapid growth, new visual loss, severe pain, orbital signs or suspected invasive malignancy need prompt specialist assessment.